Take Part in a Parkinson's Study

Tavapadon is an investigational drug being evaluated for treatment of PD.

Help us complete the breakthrough for the most advanced therapeutic candidate, Tavapadon, for the treatment of both early- and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile. A chronic neurodegenerative disorder, Parkinson’s primarily results in progressive and debilitating motor symptoms, including decreased bodily movement, slowness of movement, rigidity, tremor and postural instability, all of which result from the death of dopamine-producing neurons in the brain.

Each of the TemPo Studies will compare the investigational drug to placebo. A placebo is an inactive material, such as a sugar pill, that looks like the investigational drug, but does not contain any active drug. Placebos play an important role in clinical research studies, as they help researchers determine if an investigational drug works better or is safer than taking nothing.

Participants in the TemPo Studies will be randomly assigned (like flipping a coin) to receive the investigational drug or placebo. Your chances of receiving the investigational drug or placebo will depend on which of the two TemPo Studies you are participating in. Neither you nor the study doctor will know if you are receiving the investigational drug; however, the study doctor can find out this information if he or she feels it is necessary for your health.